| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1,8-Cineole — 1,8-cineole, also called eucalyptol, is a volatile bicyclic monoterpene ether and major active constituent of eucalyptus oil and several other aromatic plant oils (other plants such as oregano (Origanum spec.), thyme (Thymus spec.), guava (Psidium pohlianum) or sage (Salvia spec.)). Eucalyptus oil used for medicinal applications should contain at least 70% of 1,8-Cineol. It is best classified as a small-molecule phytochemical / essential-oil monoterpenoid rather than as a botanical extract. Its main established human-use identity is respiratory anti-inflammatory / mucolytic support, while its oncology relevance is preclinical and concentration-limited. Primary mechanisms (ranked):
Bioavailability / PK relevance: 1,8-cineole is orally and inhalationally absorbed and undergoes rapid systemic distribution, with CYP3A-mediated oxidation as an important metabolic route. Enteric-coated oral preparations can deliver measurable tissue exposure in airway/nasal tissues, but oncology-relevant systemic concentrations are not established. In-vitro vs systemic exposure relevance: Many anticancer studies use millimolar-range in-vitro concentrations or concentrated essential-oil fractions, which likely exceed routine achievable systemic exposure from conventional oral or inhaled use. Direct cancer-cell effects should therefore be marked as exposure-constrained unless a delivery formulation is specified. Clinical evidence status: Preclinical oncology only. There is cell-line and animal/xenograft evidence for anticancer activity, but no established cancer-directed clinical efficacy. Human clinical deployment is mainly respiratory/supportive use of eucalyptus oil or purified 1,8-cineole preparations, not antineoplastic therapy. 1,8-Cineole Cancer Mechanism Summary
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: |
| Type: |
| Snail gene may show a role in recurrence of breast cancer by downregulating E-cadherin and inducing an epithelial to mesenchymal transition. Snail promotes metastasis of breast cancer cells and overexpression of Snail is a biomarker of poor clinical outcome for patients with breast cancer. Snail, a repressor of E-cadherin and an inducer of EMT. Snail (SNAI1): A transcription factor that plays a key role in the regulation of the epithelial-to-mesenchymal transition (EMT). It suppresses the expression of epithelial markers (such as E-cadherin) and upregulates mesenchymal markers, facilitating changes in cell adhesion and motility. EMT Induction: Snail actively represses genes such as E-cadherin, a protein critical for cell–cell adhesion. Its upregulation leads to a loss of epithelial characteristics and the acquisition of a mesenchymal phenotype, enhancing migratory potential. Invasion and Metastasis: Through EMT induction, Snail facilitates tumor cell dissemination and invasion into surrounding tissues, thereby playing a central role in metastasis. Elevated levels of Snail have been observed in a variety of cancers, including breast, colorectal, pancreatic, and head and neck cancers. Elevated Snail expression is frequently associated with a worse prognosis, including lower overall survival rates and increased likelihood of metastasis. |
| 6465- | 1,8-Cin, | Eucalyptol targets PI3K/Akt/mTOR pathway to inhibit skin cancer metastasis |
| - | vitro+vivo, | Melanoma, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:409 Target#:376 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid